Pub Date : 2024-11-07DOI: 10.1016/j.leukres.2024.107617
Xianbo Huang , Xianhui Wu , Shasha Wang , Yanling Ren , Yu Xu , Chen Mei , Jie Jin , Hongyan Tong , Jiejing Qian
{"title":"Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvement: Insights from a single center","authors":"Xianbo Huang , Xianhui Wu , Shasha Wang , Yanling Ren , Yu Xu , Chen Mei , Jie Jin , Hongyan Tong , Jiejing Qian","doi":"10.1016/j.leukres.2024.107617","DOIUrl":"10.1016/j.leukres.2024.107617","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107617"},"PeriodicalIF":2.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-06DOI: 10.1016/j.leukres.2024.107612
Panayiotis D. Kontoyiannis , Arjun S. Peddireddy , Koji Sasaki, Kelly Chien, Jayastu Senapati, Guillermo Montalban-Bravo, Courtney DiNardo, Gautam Borthakur, Rashmi Kanagal-Shamanna, Carlos Bueso-Ramos, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Samuel Urrutia
{"title":"Causes of death in patients with myelodysplastic syndrome and spliceosome mutations","authors":"Panayiotis D. Kontoyiannis , Arjun S. Peddireddy , Koji Sasaki, Kelly Chien, Jayastu Senapati, Guillermo Montalban-Bravo, Courtney DiNardo, Gautam Borthakur, Rashmi Kanagal-Shamanna, Carlos Bueso-Ramos, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Samuel Urrutia","doi":"10.1016/j.leukres.2024.107612","DOIUrl":"10.1016/j.leukres.2024.107612","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107612"},"PeriodicalIF":2.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-05DOI: 10.1016/j.leukres.2024.107615
Jiwei Shen , Jiawei Li , Rui Yang , Shuang Wu , Zhimei Mu , Shi Ding , Xinyu Zhang , Meiying Duo , Ye Chen , Ju Liu
Mantle cell lymphoma (MCL) is a heterogenous disease that is one of the most challenging blood cancers due to its poor prognosis, high risk of relapse and drug resistance. Recent researches have brought significant changes in MCL patients outcomes and new clinical. Bruton's Tyrosine Kinase (BTK), a key kinase in the B-cell antigen receptor (BCR) signaling pathway, is a clinical research hot spot and plays a major role in the survival and spread of malignant B cells. The first generation of BTK inhibitors, led by ibrutinib, have shown promising results in targeted treatment. Meanwhile, several inhibitors have entered clinical studies and demonstrated outstanding therapeutic activity in clinical trials for MCL, indicating a good prospect for development. Despite these encouraging findings, the duration of response is limited, and resistance to BTK inhibitors develops in a portion of individuals. This review summarizes the pathogenesis of MCL and targeted BTK inhibitors and provides an overview of the mutations that can lead to resistance to BTK inhibitors. The purpose of this article is to review the literature describing these selective therapies and provides perspectives for their further development.
{"title":"Advances in the treatment of mantle cell lymphoma with BTK inhibitors","authors":"Jiwei Shen , Jiawei Li , Rui Yang , Shuang Wu , Zhimei Mu , Shi Ding , Xinyu Zhang , Meiying Duo , Ye Chen , Ju Liu","doi":"10.1016/j.leukres.2024.107615","DOIUrl":"10.1016/j.leukres.2024.107615","url":null,"abstract":"<div><div>Mantle cell lymphoma (MCL) is a heterogenous disease that is one of the most challenging blood cancers due to its poor prognosis, high risk of relapse and drug resistance. Recent researches have brought significant changes in MCL patients outcomes and new clinical. Bruton's Tyrosine Kinase (BTK), a key kinase in the B-cell antigen receptor (BCR) signaling pathway, is a clinical research hot spot and plays a major role in the survival and spread of malignant B cells. The first generation of BTK inhibitors, led by ibrutinib, have shown promising results in targeted treatment. Meanwhile, several inhibitors have entered clinical studies and demonstrated outstanding therapeutic activity in clinical trials for MCL, indicating a good prospect for development. Despite these encouraging findings, the duration of response is limited, and resistance to BTK inhibitors develops in a portion of individuals. This review summarizes the pathogenesis of MCL and targeted BTK inhibitors and provides an overview of the mutations that can lead to resistance to BTK inhibitors. The purpose of this article is to review the literature describing these selective therapies and provides perspectives for their further development.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107615"},"PeriodicalIF":2.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-29DOI: 10.1016/j.leukres.2024.107611
V. Wais, A. Gantner, K. Strauss, A. Neagoie, C. Weidt, J. Schnell, H. Döhner, D. Bunjes, E. Sala
Steroid-refractory acute and chronic graft-versus-host disease (SR-a/cGvHD) represents a potential life-threatening complication following allogeneic stem-cell transplantation (allo-SCT). The JAK1/2-inhibitor ruxolitinib and the extracorporeal photopheresis (ECP) have been shown to significantly improve the overall response rate (ORR) in this setting. However, about 30–40 % of high-risk patients do not respond to monotherapy and/or experience side effects. Considering the potential synergic mechanism of action of ruxolitinib and ECP and the good safety profile, we decided to investigate the role of a treatment strategy of ruxolitinib in combination with ECP in frail patients with high-risk SR-a/cGvHD. We conducted a retrospective single-center study comprising 47 patients who underwent allo-SCT from November 2018 to October 2023 and received treatment for SR-aGvHD (n=20) or SR-cGvHD (n=27) with ruxolitinib and ECP. In the SR-aGvHD group, 95 % of patients had a lower GI-tract involvement, with 80 % presenting with a grade III-IV SR-aGvHD. The ORR at day +28 was 65 %, with a 30 % CR rate. The 1-year overall survival (OS) for responders (PR and CR) was 33 % (95 % CI, 10 %-59 %). In the SR-cGvHD group, 55.6 % and 44.4 % had moderate and severe SR-cGvHD, respectively. The majority of patients (66.7 %) had a GI-involvement. The ORR at week 24 was 88 %, including 12 % CR and 76 % PR. The 1-year OS for responders was 76 % (95 % CI, 47 %-90 %). Our retrospective analysis shows that the treatment of ruxolitinib in combination with ECP has potential efficacy in patients with SR-a/cGvHD with a high-risk for transplantation-associated mortality.
{"title":"Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population","authors":"V. Wais, A. Gantner, K. Strauss, A. Neagoie, C. Weidt, J. Schnell, H. Döhner, D. Bunjes, E. Sala","doi":"10.1016/j.leukres.2024.107611","DOIUrl":"10.1016/j.leukres.2024.107611","url":null,"abstract":"<div><div>Steroid-refractory acute and chronic graft-versus-host disease (SR-a/cGvHD) represents a potential life-threatening complication following allogeneic stem-cell transplantation (allo-SCT). The JAK1/2-inhibitor ruxolitinib and the extracorporeal photopheresis (ECP) have been shown to significantly improve the overall response rate (ORR) in this setting. However, about 30–40 % of high-risk patients do not respond to monotherapy and/or experience side effects. Considering the potential synergic mechanism of action of ruxolitinib and ECP and the good safety profile, we decided to investigate the role of a treatment strategy of ruxolitinib in combination with ECP in frail patients with high-risk SR-a/cGvHD. We conducted a retrospective single-center study comprising 47 patients who underwent allo-SCT from November 2018 to October 2023 and received treatment for SR-aGvHD (n=20) or SR-cGvHD (n=27) with ruxolitinib and ECP. In the SR-aGvHD group, 95 % of patients had a lower GI-tract involvement, with 80 % presenting with a grade III-IV SR-aGvHD. The ORR at day +28 was 65 %, with a 30 % CR rate. The 1-year overall survival (OS) for responders (PR and CR) was 33 % (95 % CI, 10 %-59 %). In the SR-cGvHD group, 55.6 % and 44.4 % had moderate and severe SR-cGvHD, respectively. The majority of patients (66.7 %) had a GI-involvement. The ORR at week 24 was 88 %, including 12 % CR and 76 % PR. The 1-year OS for responders was 76 % (95 % CI, 47 %-90 %). Our retrospective analysis shows that the treatment of ruxolitinib in combination with ECP has potential efficacy in patients with SR-a/cGvHD with a high-risk for transplantation-associated mortality.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107611"},"PeriodicalIF":2.1,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142579064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-26DOI: 10.1016/j.leukres.2024.107610
Ashmitha Kumar, Arunan Jeyakumar, Alfred K. Lam, Vinod Gopalan
Background
The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).
Aim
This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.
Methodology
A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.
The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).
Results
Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.
Conclusion
This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.
背景：近年来，由于早期诊断的进步和生存期的延长，癌症幸存者的人数不断增加。现有文献表明，皮肤黑色素瘤（CM）与血液系统恶性肿瘤（HM）之间存在联系。研究目的：本研究旨在审查关于皮肤黑色素瘤与血液系统恶性肿瘤之间联系的流行病学研究，并探讨导致这种联系的遗传、生物和环境因素：方法：进行文献综述和荟萃分析，评估 HM 后患 CM 的风险，反之亦然。纳入研究的数据均报告了标准化发病率比（SIR）或危险比（HR）及95%置信区间（CI），研究采用随机效应模型对这些数据进行了汇总。使用 I² 和 Cochrane Q 检验统计量评估研究之间的异质性。采用随机效应模型对发病率数据进行了汇总。本综述已在 PROSPERO（CRD42022359887）上注册：10项研究的重点是CM患者的HM诊断，包括189094人的合并队列，11项研究的重点是HM患者的CM诊断，包括306967人的队列。CM 后 HM 的 SIR 在 1.25 到 3.12 之间，而 HM 后 CM 的 SIR 在 0.83 到 4.12 之间。合并 CM 患者中 HM 的比例为 62.4%，合并 HM 患者中 CM 的比例为 19.6%。统计异质性很高，I²值分别为99.19%和89.15%：本综述证实了同一患者的 CM 和 HM 之间存在关联。这种关联主要归因于涉及 BRAF-V600K、酪氨酸激酶通路基因、CDKN2A (P16) 和 BCL-2 的遗传因素。此外，紫外线辐射和免疫功能受损等风险因素也与这些癌症的发病率有关。
{"title":"Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review","authors":"Ashmitha Kumar, Arunan Jeyakumar, Alfred K. Lam, Vinod Gopalan","doi":"10.1016/j.leukres.2024.107610","DOIUrl":"10.1016/j.leukres.2024.107610","url":null,"abstract":"<div><h3>Background</h3><div>The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).</div></div><div><h3>Aim</h3><div>This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.</div></div><div><h3>Methodology</h3><div>A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.</div><div>The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).</div></div><div><h3>Results</h3><div>Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.</div></div><div><h3>Conclusion</h3><div>This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107610"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-26DOI: 10.1016/j.leukres.2024.107599
Josefine Krüger , Igor Wolfgang Blau , Olga Blau , Alice Bettelli , Laura Rocchi , Massimo Bocchi , Jan Krönke , Lars Bullinger , Ulrich Keller , Axel Nogai
Multiple myeloma is an aggressive neoplasm of plasma cells. While numerous drugs have gained approval, the absence of established predictive markers for individual drug responses poses a challenge. In this study, we explored the microwell- and fluorescence-based Cellply CC-Array® technology for high-throughput analysis of in vitro drug responses as a potential predictive marker for patient treatment outcomes. Furthermore, we investigated its application for evaluating effector cell effectiveness. Mononuclear cells were isolated from the bone marrow of 22 patients, and in vitro drug response of primary myeloma cells was analyzed. In vitro responses towards melphalan, bortezomib, and dexamethasone in primary patient samples correlated with clinical response of the patients. The approach exhibited limitations in identifying sensitivity towards lenalidomide, daratumumab, and elotuzumab due to limited culturing time caused by poor myeloma viability in vitro. Through the analysis of cell proximity, the platform enabled the assessment of individual anti-tumor activity from NK and T cells. In summary, the CC-Array microwell technology allowed assessment of myeloma cell responses to selected drugs used in multiple myeloma therapy in vitro. To further validate these in vitro results against in vivo outcomes, screening a larger cohort is necessary.
多发性骨髓瘤是一种浆细胞侵袭性肿瘤。虽然许多药物已获得批准，但缺乏针对个体药物反应的既定预测指标构成了挑战。在这项研究中，我们探索了基于微波和荧光的 Cellply CC-Array® 技术，该技术可用于体外药物反应的高通量分析，是患者治疗效果的潜在预测标志物。此外，我们还研究了该技术在评估效应细胞有效性方面的应用。我们从 22 名患者的骨髓中分离出单核细胞，分析了原发性骨髓瘤细胞的体外药物反应。原代患者样本对美法仑、硼替佐米和地塞米松的体外反应与患者的临床反应相关。由于骨髓瘤体外存活率低导致培养时间有限，这种方法在确定对来那度胺、达拉曲单抗和艾洛妥珠单抗的敏感性方面存在局限性。通过分析细胞接近性，该平台能够评估 NK 和 T 细胞的个体抗肿瘤活性。总之，CC-Array 微阵列技术可以在体外评估骨髓瘤细胞对用于多发性骨髓瘤治疗的特定药物的反应。为了进一步验证这些体外结果与体内结果的一致性，有必要对更大的群体进行筛选。
{"title":"In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology","authors":"Josefine Krüger , Igor Wolfgang Blau , Olga Blau , Alice Bettelli , Laura Rocchi , Massimo Bocchi , Jan Krönke , Lars Bullinger , Ulrich Keller , Axel Nogai","doi":"10.1016/j.leukres.2024.107599","DOIUrl":"10.1016/j.leukres.2024.107599","url":null,"abstract":"<div><div>Multiple myeloma is an aggressive neoplasm of plasma cells. While numerous drugs have gained approval, the absence of established predictive markers for individual drug responses poses a challenge. In this study, we explored the microwell- and fluorescence-based Cellply CC-Array® technology for high-throughput analysis of <em>in vitro</em> drug responses as a potential predictive marker for patient treatment outcomes. Furthermore, we investigated its application for evaluating effector cell effectiveness. Mononuclear cells were isolated from the bone marrow of 22 patients, and <em>in vitro</em> drug response of primary myeloma cells was analyzed. <em>In vitro</em> responses towards melphalan, bortezomib, and dexamethasone in primary patient samples correlated with clinical response of the patients. The approach exhibited limitations in identifying sensitivity towards lenalidomide, daratumumab, and elotuzumab due to limited culturing time caused by poor myeloma viability <em>in vitro</em>. Through the analysis of cell proximity, the platform enabled the assessment of individual anti-tumor activity from NK and T cells. In summary, the CC-Array microwell technology allowed assessment of myeloma cell responses to selected drugs used in multiple myeloma therapy <em>in vitro</em>. To further validate these <em>in vitro</em> results against <em>in vivo</em> outcomes, screening a larger cohort is necessary.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107599"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-24DOI: 10.1016/j.leukres.2024.107609
Susanne Isfort, Carlo Gambacorti-Passerini, Tim H. Brümmendorf, B. Douglas Smith, Simon Purcell, Maja Strecker, Huadong Zhao, Luke Kuttschreuter, Jane Apperley
{"title":"The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis","authors":"Susanne Isfort, Carlo Gambacorti-Passerini, Tim H. Brümmendorf, B. Douglas Smith, Simon Purcell, Maja Strecker, Huadong Zhao, Luke Kuttschreuter, Jane Apperley","doi":"10.1016/j.leukres.2024.107609","DOIUrl":"10.1016/j.leukres.2024.107609","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107609"},"PeriodicalIF":2.1,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan","authors":"Ming-Chung Kuo , Chien-Chin Lin , Hsuan-Yu Lin, Jyh-Pyng Gau, Ming-Chung Wang, Ming-Chih Chang, Tsung-Chih Chen, Shih-Peng Yeh, Yeu-Chin Chen, Cih-En Huang, I-Ju Chiang, Hao-Wei Cheng, Yee-Ming Lee, Fan-Chen Ku, Cheng-Shyong Chang","doi":"10.1016/j.leukres.2024.107601","DOIUrl":"10.1016/j.leukres.2024.107601","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107601"},"PeriodicalIF":2.1,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-22DOI: 10.1016/j.leukres.2024.107600
Martin S. Staege
{"title":"The phylogenetic age paradox of non-coding RNAs","authors":"Martin S. Staege","doi":"10.1016/j.leukres.2024.107600","DOIUrl":"10.1016/j.leukres.2024.107600","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107600"},"PeriodicalIF":2.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-22DOI: 10.1016/j.leukres.2024.107602
Kelly S. Chien, Juan Jose Rodriguez-Sevilla, Yesid Alvarado, Guillermo Montalban-Bravo, Danielle E. Hammond, Mahesh Swaminathan, Alexandre Bazinet, Jacqueline Kimberley, Kristy Bodden, Heather Schneider, Xiao Qin Dong, Sherry A. Pierce, Xuelin Huang, Elias J. Jabbour, Hagop M. Kantarjian, Guillermo Garcia-Manero
{"title":"A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure","authors":"Kelly S. Chien, Juan Jose Rodriguez-Sevilla, Yesid Alvarado, Guillermo Montalban-Bravo, Danielle E. Hammond, Mahesh Swaminathan, Alexandre Bazinet, Jacqueline Kimberley, Kristy Bodden, Heather Schneider, Xiao Qin Dong, Sherry A. Pierce, Xuelin Huang, Elias J. Jabbour, Hagop M. Kantarjian, Guillermo Garcia-Manero","doi":"10.1016/j.leukres.2024.107602","DOIUrl":"10.1016/j.leukres.2024.107602","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107602"},"PeriodicalIF":2.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号